Biovail's brand play

Biovail Corp.'s $409.5 million purchase of North American rights to Aventis Pharmaceuticals' line of Cardizem diltiazem calcium channel blockers may look like a lot of money to spend on a group of branded generic products with declining sales. But for

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE